Q-omics provides the consensus-scored RSPO3 profile across patient tissues and cancer cell-line models. RSPO3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RSPO3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RSPO3 RNA expression shows 20,350 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where RSPO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPO3 survival associations across molecular data types. RSPO3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPO3 RNA expression–survival associations across cancer types. High RSPO3 expression shows unfavorable associations in UVM, KIRP and BLCA, but favorable associations in SKCM, KIRC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for RSPO3 RNA expression.
This table summarizes RSPO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RSPO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPO3 shows lower tumor expression in KIRC, BLCA, THCA, COAD, LIHC and UCEC. The KIRC box plot shows higher RSPO3 RNA expression in normal versus tumor tissue (log2 FC = −1.490, t-test p < 0.001).
This table shows molecular features associated with RSPO3 in patient tissues and cancer cell lines. In patient samples, RSPO3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
